- Previous Close
12.33 - Open
12.51 - Bid 12.49 x 100
- Ask 15.88 x 100
- Day's Range
12.30 - 12.72 - 52 Week Range
6.40 - 19.24 - Volume
112,969 - Avg. Volume
238,347 - Market Cap (intraday)
325.19M - Beta (5Y Monthly) 1.29
- PE Ratio (TTM)
-- - EPS (TTM)
-2.65 - Earnings Date Apr 28, 2025 - May 2, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
19.83
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, a neuromodulation device that enhance symptoms for patients with heart failure by delivering electrical pulses to baroreceptors. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
www.cvrx.comRecent News: CVRX
View MorePerformance Overview: CVRX
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CVRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CVRX
View MoreValuation Measures
Market Cap
325.19M
Enterprise Value
269.69M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.50
Price/Book (mrq)
4.58
Enterprise Value/Revenue
5.26
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-116.91%
Return on Assets (ttm)
-29.91%
Return on Equity (ttm)
-81.58%
Revenue (ttm)
51.29M
Net Income Avi to Common (ttm)
-59.97M
Diluted EPS (ttm)
-2.65
Balance Sheet and Cash Flow
Total Cash (mrq)
105.93M
Total Debt/Equity (mrq)
70.98%
Levered Free Cash Flow (ttm)
-20.93M